Autolus Therapeutics plc
Most Recent
T-Cell Pipeline Is a Key Growth Driver for Autolus Therapeutics
The 12-month consensus analyst recommendation for Autolus Therapeutics (AUTL) on September 25 is a “strong buy.”
Most Recent
The 12-month consensus analyst recommendation for Autolus Therapeutics (AUTL) on September 25 is a “strong buy.”